Cue Biopharma
Siddhartha Shrivastava, Ph.D. has worked for several companies since 2012. Siddhartha began their career at Cornell University (WCMC-TMHRI) as a Research Scientist in 2012. In 2013, they joined Thermo Fisher Scientific as a Principal Scientist/Group Leader in Downstream Process Development and then as a Senior Scientist/Team Lead in the same field. From 2015 to 2020, they worked for Sanofi, first as the Head of North America Technical Operations - EMG, then as Senior Director of Global External Manufacturing NA, and finally as Associate Director of Global Manufacturing Sciences and Technology (Process Engineering & Development). In 2020, they joined Flagship Pioneering as Vice President and Head of Global Technical Operations, and in 2021 they moved to Cue Biopharma as Vice President, Head of CMC and Global Technical Operations.
Siddhartha Shrivastava, Ph.D. has an extensive educational background. Siddhartha began their studies in 1999 when they earned a Bachelor's degree in Biochemistry from Rani Durgavati Vishwavidyalaya. Siddhartha then went on to earn a Master's degree in Biochemistry from Devi Ahilya Vishwavidyalaya in 2004. Following this, they earned a Doctor of Philosophy (PhD) in Biochemistry from Banaras Hindu University in 2010. Lastly, they served as a Post Doctoral Research Associate in Chemical Engineering at Rensselaer Polytechnic Institute from 2010 to 2012.
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.